Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. (2018)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.euo.2018.02.006
PubMed Identifier: 29911685
Publication URI: http://europepmc.org/abstract/MED/29911685
Type: Journal Article/Review
Volume: 1
Parent Publication: European urology oncology
Issue: 1
ISSN: 2588-9311